Page last updated: 2024-11-04

suramin and Prostatic Neoplasms

suramin has been researched along with Prostatic Neoplasms in 155 studies

Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.

Prostatic Neoplasms: Tumors or cancer of the PROSTATE.

Research Excerpts

ExcerptRelevanceReference
"The goal of the current study was to determine the prostate-specific antigen (PSA) and objective response rates and the pharmacokinetics associated with a monthly x 3 one-hour infusion of suramin in 58 patients with hormone-refractory prostate carcinoma."9.11A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma. ( Arrieta, R; Cohn, H; Garcia, J; Giannone, L; Karrison, T; Kugler, J; Ratain, MJ; Stadler, WM; Troeger, T; Vogelzang, NJ; Vokes, EE, 2004)
"Using a fixed higher-dose schedule, the efficacy and toxicity of suramin plus hydrocortisone were assessed in patients with metastatic hormone-refractory prostate carcinoma (HRPC)."9.09Fixed higher dose schedule of suramin plus hydrocortisone in patients with hormone refractory prostate carcinoma a multicenter Phase II study. ( Beltrán, C; Berián, JM; Brugarolas, A; Calvo, E; Cortés, J; de Irala, J; Martínez-Monge, R; Rebollo, J; Rodríguez, J; Sureda, M, 2001)
" Absolute hypophosphatemia developed in two patients with more prolonged suramin treatment due to Fanconi's syndrome."9.07Suramin-induced weakness from hypophosphatemia and mitochondrial myopathy. Association of suramin with mitochondrial toxicity in humans. ( Miles, JM; Rago, RP; Spriggs, DR; Sufit, RL; Wilding, G, 1994)
"This paper presents a retrospective review of 6 cases of severe neutropenia attributed to suramin, the response to granulocyte-colony stimulating factor (G-CSF) and the possible mechanism."7.69Suramin-induced neutropenia. ( Dawson, NA; Figg, WD; Headlee, DJ; Lush, RM; Steinberg, SM; Tompkins, AC, 1996)
"The antiparasitic drug, suramin, has antiproliferative effects in human carcinoma cells."7.68Disruption of cellular energy balance by suramin in intact human prostatic carcinoma cells, a likely antiproliferative mechanism. ( Cheng, AL; Mitchen, J; Oberley, T; Rago, R; Wilding, G, 1991)
"Suramin is a polyanionic agent which has been found to be an effective antineoplastic agent against various human tumors including adrenal, renal and prostatic cancer, and osteosarcoma."5.29Suramin suppresses hypercalcemia and osteoclastic bone resorption in nude mice bearing a human squamous cancer. ( Boyce, BF; Dunstan, C; Mundy, GR; Rhine, C; Williams, P; Yoneda, T, 1995)
"The goal of the current study was to determine the prostate-specific antigen (PSA) and objective response rates and the pharmacokinetics associated with a monthly x 3 one-hour infusion of suramin in 58 patients with hormone-refractory prostate carcinoma."5.11A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma. ( Arrieta, R; Cohn, H; Garcia, J; Giannone, L; Karrison, T; Kugler, J; Ratain, MJ; Stadler, WM; Troeger, T; Vogelzang, NJ; Vokes, EE, 2004)
"Patients with histologically confirmed advanced hormone-refractory adenocarcinoma of the prostate were randomized to receive suramin at a low dose (n = 129; median age, 69 years), an intermediate dose (n = 129; median age, 71 years), or a high dose (n = 127; median age, 70 years) as part of the Intergroup 0159/Cancer and Leukemia Group B 9480 trial."5.11Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480. ( Ahles, TA; Herndon, JE; Holland, JC; Kornblith, AB; Marshall, ME; Palchak, D; Petrylak, D; Ratain, MJ; Small, EJ; Stadler, W; Vogelzang, NJ; Wilding, G, 2004)
"Overall mean reductions in combined pain and opioid analgesic intake were greater for suramin plus HC (rank sum P =."5.09Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. ( Chen, L; Eisenberger, M; Lenehan, PF; Marshall, ME; Meyer, M; Meyers, FJ; Natale, RB; Reyno, LM; Slichenmyer, WJ; Small, EJ, 2000)
"Using a fixed higher-dose schedule, the efficacy and toxicity of suramin plus hydrocortisone were assessed in patients with metastatic hormone-refractory prostate carcinoma (HRPC)."5.09Fixed higher dose schedule of suramin plus hydrocortisone in patients with hormone refractory prostate carcinoma a multicenter Phase II study. ( Beltrán, C; Berián, JM; Brugarolas, A; Calvo, E; Cortés, J; de Irala, J; Martínez-Monge, R; Rebollo, J; Rodríguez, J; Sureda, M, 2001)
" Absolute hypophosphatemia developed in two patients with more prolonged suramin treatment due to Fanconi's syndrome."5.07Suramin-induced weakness from hypophosphatemia and mitochondrial myopathy. Association of suramin with mitochondrial toxicity in humans. ( Miles, JM; Rago, RP; Spriggs, DR; Sufit, RL; Wilding, G, 1994)
"Suramin has shown promising activity against prostate and breast cancer but is severely neurotoxic."5.07Suramin for breast and prostate cancer: a pilot study of intermittent short infusions without adaptive control. ( George, N; Howell, A; Margison, J; Ranson, M; Thomson, Y; van der Water, L; Woll, PJ, 1994)
" As a result, mitoxantrone plus prednisone has been demonstrated to be a useful palliative therapy that provides improvements in pain and quality of life for approximately 40% of those treated."4.81Treatment of hormone refractory prostate cancer. ( Knox, JJ; Moore, MJ, 2001)
"This paper presents a retrospective review of 6 cases of severe neutropenia attributed to suramin, the response to granulocyte-colony stimulating factor (G-CSF) and the possible mechanism."3.69Suramin-induced neutropenia. ( Dawson, NA; Figg, WD; Headlee, DJ; Lush, RM; Steinberg, SM; Tompkins, AC, 1996)
"The antiparasitic drug, suramin, has antiproliferative effects in human carcinoma cells."3.68Disruption of cellular energy balance by suramin in intact human prostatic carcinoma cells, a likely antiproliferative mechanism. ( Cheng, AL; Mitchen, J; Oberley, T; Rago, R; Wilding, G, 1991)
" There was a dose-response relationship between dose and toxicity."2.70Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480. ( Halabi, S; Hars, V; Marshall, E; Palchak, D; Petrylak, D; Rago, R; Ratain, MJ; Rosner, G; Small, EJ; Stadler, W; Vogelzang, NJ; Wilding, G, 2002)
"Suramin was administered on a 78-day fixed dosing schedule (one cycle), and suramin treatment cycles were repeated every 6 months for a total of four cycles."2.69Androgen deprivation and four courses of fixed-schedule suramin treatment in patients with newly diagnosed metastatic prostate cancer: A Southwest Oncology Group Study. ( Crawford, ED; Eisenberger, MA; Fisher, EI; Hussain, M; O'Connor, J; Petrylak, DP; Small, EJ; Wood, DP, 2000)
"Suramin was given i."2.69Phase I study of suramin combined with doxorubicin in the treatment of androgen-independent prostate cancer. ( Amato, RJ; Banks, ME; Bugazia, NA; Logothetis, CJ; Madden, T; Millikan, RE; Newman, RA; Pagliaro, LC; Tu, SM, 1998)
"Suramin has limited, but significant, efficacy even in chemotherapy- and hormone-refractory prostate cancer, without serious toxicity."2.69Suramin treatment in hormone- and chemotherapy-refractory prostate cancer. ( Allolio, B; Garcia-Schürmann, JM; Haupt, G; Pastor, J; Schulze, H; Senge, T, 1999)
"Suramin was administered initially as a 6-day continuous infusion for 10 consecutive weeks and then for 6 days every 28 days for a maximum of 6 months."2.69Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma. ( Allegrini, G; Antonuzzo, A; Conte, P; Danesi, R; Del Tacca, M; Falcone, A; Masi, G; Monica, L; Pfanner, E; Ricci, S, 1999)
"Management of prostate cancer progression after failure of initial hormonal therapy is controversial."2.69Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal. ( Bergan, R; Brawley, OW; Cooper, MR; Dawson, N; Figg, WD; Headlee, D; Linehan, WM; Patronas, N; Reed, E; Sartor, O; Sausville, E; Senderowicz, A; Steinberg, SM; Sutherland, M, 1998)
"Significant neurologic toxicity can result from therapy with suramin, even when dosing is designed to avoid exposure to plasma concentrations greater than 350 micrograms/mL."2.68Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin. ( Bitton, RJ; Bowden, C; Cooper, MR; Dalakas, MC; Figg, WD; Headlee, D; Myers, CE; Reed, E; Venzon, DJ, 1995)
"Ten patients with hormone-refractory prostate cancer received a fixed dosing scheme of suramin infusion in combination with weekly epidoxorubicin at 25 mg/m2."2.68Suramin/epidoxorubicin association in hormone-refractory prostate cancer: preliminary results of a pilot phase II study. ( Boccardo, F; Canobbio, L; Esposito, M; Granetto, C; Miglietta, L; Vannozzi, MO, 1997)
"Patients with stage D2 and poor-prognosis stage D1 prostate cancer were given suramin on a pharmacokinetically derived dosing schedule to maintain suramin concentrations between 175 and 300 micrograms/mL."2.68Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer. ( Bergan, RC; Cooper, MR; Dawson, NA; Figg, WD; Myers, CE; Reed, E; Sartor, O; Sausville, EA; Senderowicz, AM; Steinberg, SM; Tompkins, A; Weinberger, B, 1997)
"Suramin is an investigational drug that has shown therapeutic activity in hormone-refractory metastatic prostate cancer in Phase I/II trials."2.68A prospective study of suramin-induced peripheral neuropathy. ( Chaudhry, V; Cornblath, DR; Eisenberger, MA; Griffin, JW; Sheikh, K; Sinibaldi, VJ, 1996)
"We used population pharmacokinetic-parameter estimates and designed a fixed dosing schedule to maintain plasma suramin concentrations between 100 and 300 micrograms/mL and then evaluated its performance."2.68Development and validation of a pharmacokinetically based fixed dosing scheme for suramin. ( Egorin, MJ; Eisenberger, MA; Reyno, LM; Sinibaldi, VJ; Sridhara, R; Zuhowski, EG, 1995)
" We conclude that: (1) serial electrophysiologic monitoring is helpful for early detection of suramin-induced neuropathy; and (2) fixed dosing schedule of suramin without adaptive control does not lead to an increased incidence of demyelinating neuropathy when compared to adaptively controlled dosing schedules."2.68Evaluation of neuropathy in patients on suramin treatment. ( Arora, R; Dhand, UK; Janisch, L; Kobayashi, K; Martin, B; Petersen, MV; Ratain, MJ; Soliven, B; Vogelzang, NJ; Vokes, EE, 1997)
" There appeared to be a cumulative dose-response relationship to the development of glucocorticoid insufficiency, with no instances being observed at doses < 4."2.68Mineralocorticoid insufficiency due to suramin therapy. ( Janisch, L; Kobayashi, K; Ratain, MJ; Vogelzang, NJ; Vokes, EE; Weiss, RE, 1996)
"Suramin is a newer agent employed in the management of prostate cancer."2.68Suramin as adjuvant therapy with radical prostatectomy. ( Chou, P; Guinan, P; Ray, V; Rubenstein, M; Saffrin, R; Shaw, M, 1996)
"Using this dosing schedule, suramin has limited activity against hormone-refractory metastatic prostate cancer."2.68Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy. ( Belldegrun, A; deKernion, J; Graves, MC; Landaw, EM; McBride, JH; Mendoza, EF; Mondino, B; Rosen, PJ; Turcillo, P, 1996)
"Suramin was given as intermittent infusions at fixed doses on days 1-5 and thereafter dosing was guided by adaptive control with feedback to maintain plasma suramin concentrations between 300-175 micrograms/ml."2.68Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables. ( Bergan, RC; Cooper, MR; Dawson, NA; Figg, WD; Headlee, DJ; Myers, CE; Sartor, O; Sausville, EA; Steinberg, SM; Thibault, A, 1995)
"Suramin has limited efficacy in patients with androgen-independent prostate cancer who have had disease progression after hydrocortisone."2.68Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer. ( Curley, T; Dnistrian, A; Kelly, WK; Leibretz, C; Scher, HI; Schwartz, M, 1995)
"Suramin is a synthetic polysulfonated naphthylurea which has been used for the treatment of African trypanosomiasis and onchocerciasis, but since the mid-1980s has received attention as a possible antiretroviral and antineoplastic agent."2.68A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: toxicity and response. ( Bitton, RJ; Bowden, CJ; Cooper, MR; Dawson, NA; Figg, WD; Headlee, D; Myers, CE; Reed, E; Sartor, O; Weinberger, MS, 1996)
"This phase I study was designed with the following objectives: (1) to describe the overall and dose-limiting toxicity (DLT) of suramin administered by intermittent short intravenous infusions until DLT or disease progression; (2) to determine the ability of an adaptive control with feedback (ACF) dosing strategy to maintain suramin plasma concentrations within a preselected range; (3) to develop a population model of suramin pharmacokinetics; and (4) to identify preliminary evidence of antitumor activity."2.68Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer. ( Eisenberger, MA; Hemady, RK; Jacobs, SC; Jodrell, DI; Lowitt, MH; Reyno, LM; Sinibaldi, VJ; Sridhara, R; Tkaczuk, KH; Zuhowski, EG, 1995)
"Suramin is a promising agent for the treatment of hormone-refractory metastatic prostate cancer."2.68Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer. ( Janish, L; Kobayashi, K; Ratain, MJ; Soliven, B; Vogelzang, NJ; Vokes, EE, 1995)
"Three cohorts of patients with advanced prostate cancer that progressed despite castrate levels of testosterone received oral hydrocortisone plus suramin administered in the following manners: (1) a loading dose of suramin followed by a continuous infusion using an adaptive control program (cohort A); (2) an intermittent schedule using a simplified adaptive control schedule (cohort B); and (3) an empiric dosing regimen (cohort C)."2.68Suramin and hydrocortisone: determining drug efficacy in androgen-independent prostate cancer. ( Cohen, L; Curley, T; Dnistrian, A; Kelly, WK; Leibertz, C; Mazumdar, M; Pfister, D; Scher, HI; Schwartz, M; Vlamis, V, 1995)
"This study aimed to (1) develop a population pharmacokinetic model for suramin; (2) use Bayesian methods to assess suramin pharmacokinetics in individual patients; (3) use individual patients' pharmacokinetic parameter estimates to individualize suramin dose and schedule and maintain plasma suramin concentrations within predetermined target ranges; and (4) assess the feasibility of outpatient administration of suramin by intermittent, short infusions."2.67Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer. ( Egorin, MJ; Eisenberger, MA; Jodrell, DI; Novak, MJ; Reyno, LM; Sinibaldi, VJ; Sridhara, R; Tkaczuk, KH; Zuhowski, EG, 1994)
"Suramin is known to inhibit the growth of malignant prostate carcinoma cells in vitro."2.67Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. ( Choyke, P; Cooper, M; Dawson, N; LaRocca, R; Myers, C; Stein, C; Steinberg, S; Uhrich, MM; Walther, MM; Weiss, G, 1992)
"Mitomycin C 12 mg/m2 was given every 5 weeks starting on day 14."2.67Suramin in combination with mitomycin C in hormone-resistant prostate cancer. A phase II clinical study. ( de Wet, M; Falkson, G; Lotz, BP; Potgieter, HC; Raats, JI; Rapoport, BL, 1993)
"Hormone refractory prostate cancer remains a challenge."2.43Clinical trials in metastatic prostate cancer--has there been real progress in the past decade? ( Bhandari, MS; Hussain, M; Petrylak, DP, 2005)
"Suramin has significantly enhanced the evolution of our knowledge in several areas of prostate cancer biology and treatment."2.41Suramin's development: what did we learn? ( Dahut, W; Figg, WD; Kaur, M; Reed, E; Sartor, O, 2002)
"Death from prostate cancer is associated with objective and biochemical progression following hormonal manipulations often described as hormone refractory prostate cancer (HRPCA)."2.41Current status of cytotoxic chemotherapy in hormone refractory prostate cancer. ( Heidenreich, A; Hofmann, R; von Knobloch, R, 2001)
"In the United States, prostate cancer is the most commonly diagnosed cancer and the second leading cause of cancer death in men."2.40Chemotherapy in advanced prostate cancer. ( Beedassy, A; Cardi, G, 1999)
"Metastatic prostate cancer is a leading cause of cancer-related death in men."2.40Treatment options in androgen-independent prostate cancer. ( Lara, PN; Meyers, FJ, 1999)
"Historically, hormone-refractory prostate cancer has not been routinely treated with chemotherapy, based on perceptions that single agents were not all that active, this patient population was too fragile to receive such therapy, responses were virtually impossible to verify given the rarity of bidimensionally measurable disease, and, if seen, responses were not clinically meaningful."2.40Androgen-independent prostate cancer: not so chemorefractory after all. ( Roth, BJ, 1999)
"The term "hormone-refractory" prostate cancer has evolved to include patients with a spectrum of diseases."2.39Hormone-refractory (D3) prostate cancer: refining the concept. ( Kelly, WK; Scher, HI; Steineck, G, 1995)
"Suramin has been reintroduced in trials of chemohormonal intervention."2.39[Recent multicenter study protocols in the USA for patients with metastatic prostatic carcinoma]. ( Crawford, ED; DeAntoni, E, 1995)
"the majority."2.39Apoptosis: therapeutic significance in the treatment of androgen-dependent and androgen-independent prostate cancer. ( Kyprianou, N, 1994)
"By 1994, the number of cases of prostate cancer diagnosed will increase by 50% over a 2-year period."2.39Prostate cancer: how can a common disease be so controversial? ( Kelly, WK; Scher, HI, 1994)
"The treatment against hormone relapsing prostate cancer was examined clinically, experimentally and by a review of the literature."2.39[Treatment of advanced prostate cancer]. ( Akino, H; Aoki, Y; Fujita, T; Iwaoka, K; Miwa, Y; Okada, K; Saikawa, S; Suzuki, Y, 1994)
"In recent years immunotherapy of prostate cancer has developed into an innovative field of investigation."2.38[Immunotherapy of prostate cancer]. ( Schulze, H; Sommerfeld, HJ, 1993)
"Previous in vitro studies on prostate cancer cells suggest a role for PAR-2 in prostate cancer metastasis."1.33The membrane-anchored serine protease, TMPRSS2, activates PAR-2 in prostate cancer cells. ( Greer, B; Hawthorne, S; Hooper, J; Quigley, J; Walker, B; Wilson, S; Zijlstra, A, 2005)
"A higher dosage of suramin (200 mumol/L) had a cytotoxic effect on PC-3M cells, while lower dosages from 10 to 100 mumol/L produced a predominant inhibiting effect."1.32[Influence of suramin on the proliferation of prostatic carcinoma cells PC-3M]. ( Feng, W; Lu, GC; Xiao, YJ; Xing, YF; Zeng, FQ; Zhang, QJ, 2003)
"Suramin has been shown to have an effect on bone resorption in in vitro models."1.31Suramin administration is associated with a decrease in serum calcium levels. ( Figg, WD; Linehan, WM; Myers, CE; Rehak, NN; Venzon, D; Walther, MM, 2000)
"Exposure of 1E8 and 2B4 prostate cancer cells to ATP resulted in p38 activation in a concentration- and time-dependent manner."1.31[Activation of p38 and c-Jun NH2-terminal kinase mitogen-activated protein kinases in human prostate carcinoma cell lines with different metastatic potentials]. ( Fang, W; He, C; Heng, W; Li, H; Wu, B; You, J; Zheng, J, 2001)
"Hormone-refractory prostate cancer (HRPC) patients often have nonmeasurable disease."1.30Evaluation of biomarkers of survival response in hormone-refractory prostate cancer patients treated with suramin. ( Egorin, MJ; Eisenberger, MA; Reyno, LM; Sinibaldi, VJ; Sridhara, R, 1998)
"Micrometastases were identified in bone and liver 1 day after inoculation and grew to form established metastatic foci in all embryos."1.30A chick embryo model for metastatic human prostate cancer. ( Endo, Y; Imao, T; Kobayashi, T; Koshida, K; Namiki, M; Sasaki, T; Uchibayashi, T, 1998)
"Suramin is a novel cytostatic/cytotoxic agent that is currently undergoing clinical trials in the treatment of hormone- and chemo-refractory tumors."1.30Apoptosis and clonogenic cell death in PC3 human prostate cancer cells after treatment with gamma radiation and suramin. ( Bump, EA; Coleman, CN; Palayoor, ST; Teicher, BA, 1997)
"Suramin has demonstrated modest activity against prostate cancer and is being investigated in clinical trials."1.30Acute renal failure in a patient receiving treatment with suramin. ( Harbour, D; Liebmann, J; Smith, A, 1997)
"Human prostate cancer cells (PC-3) were exposed to single doses of ionizing irradiation, and the immediate protein phosphorylation events were temporally correlated with induction of apoptosis."1.30Transient tyrosine phosphorylation of p34cdc2 is an early event in radiation-induced apoptosis of prostate cancer cells. ( Bains, A; Kyprianou, N; Rhee, JG, 1997)
"No significant difference in time to disease progression or survival was observed between African Americans (n = 4) and the other 39 patients."1.30Similar clinical outcomes in African-American and non-African-American males treated with suramin for metastatic prostate cancer. ( Bergan, RC; Dawson, NA; Figg, WD; Headlee, D; Reed, E; Steinberg, SM; Tompkins, A; Walls, RG, 1997)
"Metastatic prostate cancer is a growing health problem and is the second leading cause of cancer death in men."1.30Management of progressive metastatic prostate cancer. ( Dawson, NA; Waselenko, JK, 1997)
"Suramin is an experimental antineoplastic agent which is currently being tested in clinical trials for its utility in treating breast and prostate cancer."1.30Role of ceramide in suramin-induced cancer cell death. ( Gill, JS; Windebank, AJ, 1997)
"Suramin is an anthelmintic drug that recently has been shown to have clinical efficacy in the treatment of patients with some advanced malignancies, including prostate carcinoma."1.29Effect of suramin on the mitogenic response of the human prostate carcinoma cell line PC-3. ( Ewing, MW; Gnarra, JR; Linehan, WM; Liu, SC; Meyers, CE; Walther, MM, 1993)
"Suramin treatment prior to irradiation inhibited this radiation-induced cell death."1.29Combined antitumor effect of suramin plus irradiation in human prostate cancer cells: the role of apoptosis. ( Eddy, HA; Jacobs, SC; Kyprianou, N; Sklar, GN, 1993)
"Suramin has long been used in the treatment of onchocerciasis and trypanosomiasis."1.29[Cutaneous drug reaction caused by suramin in 4 patients with metastatic prostate cancer]. ( Dieckmann, KP; Gollnick, H; Handke, A; Tebbe, B; Wichterich, K, 1994)
"His suramin therapy was discontinued, but his serum creatinine level continued to rise to 10."1.29Acute renal toxicity associated with suramin in the treatment of prostate cancer. ( Bergan, RC; Cooper, MR; Figg, WD; Headlee, D; Humphrey, J; Reed, E; Sartor, O; Thibault, A, 1994)
"Suramin is an effective antitumor agent in hormone-refractory prostate cancer, but its mechanism(s) of action is not well understood."1.29Inhibition of fibroblast hyaluronic acid production by suramin. ( August, EM; Cysyk, RL; Duncan, KL; Malinowski, NM, 1993)
"Suramin has shown antitumour activity in vitro and in vivo."1.29The synergistic and antagonistic effects of cytotoxic and biological agents on the in vitro antitumour effects of suramin. ( Lopez Lopez, R; Peters, GJ; Pinedo, HM; van Rijswijk, RE; Wagstaff, J, 1994)
"Dunning-G rat prostate cancer cells transfected with a bcl-2 expression vector demonstrated resistance to apoptosis induced by adriamycin and, to a lesser extent, suramin."1.29Combination adriamycin and suramin induces apoptosis in bcl-2 expressing prostate carcinoma cells. ( Campbell, ML; Fernandez, A; Marin, MC; McConnell, K; McDonnell, TJ; Tu, SM; von Eschenbach, AC, 1995)
"Suramin is a polyanionic agent which has been found to be an effective antineoplastic agent against various human tumors including adrenal, renal and prostatic cancer, and osteosarcoma."1.29Suramin suppresses hypercalcemia and osteoclastic bone resorption in nude mice bearing a human squamous cancer. ( Boyce, BF; Dunstan, C; Mundy, GR; Rhine, C; Williams, P; Yoneda, T, 1995)
"Upon testing this hypothesis in prostate cancer cell lines, we found that the most conspicuous effect of suramin was to increase the tyrosine phosphorylation of several distinct proteins."1.28Suramin rapidly alters cellular tyrosine phosphorylation in prostate cancer cell lines. ( Borner, MM; McLellan, CA; Myers, CE; Sartor, O, 1992)
"have previously reported that prostate cancer cell motility was essential for tumor cell metastasis."1.28The effects of basic fibroblast growth factor and suramin on cell motility and growth of rat prostate cancer cells. ( Coffey, DS; Isaacs, WB; Pienta, KJ; Vindivich, D, 1991)
"Suramin is a trypanocidal drug that has generated recent interest as an antineoplastic agent because of its ability to inhibit the binding of growth factors to their cell surface receptors."1.28Inhibition of prostatic tumor cell proliferation by suramin: alterations in TGF alpha-mediated autocrine growth regulation and cell cycle distribution. ( Kim, JH; Kozlowski, JM; Lee, C; Sherwood, ER; Sutkowski, DM, 1991)
" The same dosing regimen found to be ineffective in blocking the restoration of the involuted prostate of castrated rats resulted in a significant reduction in the growth rate of AT-2 tumors."1.28Differential effects of growth factor antagonists on neoplastic and normal prostatic cells. ( Isaacs, JT; Isaacs, WB; Morton, RA, 1990)

Research

Studies (155)

TimeframeStudies, this research(%)All Research%
pre-19901 (0.65)18.7374
1990's124 (80.00)18.2507
2000's28 (18.06)29.6817
2010's1 (0.65)24.3611
2020's1 (0.65)2.80

Authors

AuthorsStudies
Wang, Y1
Ma, S1
Ruzzo, WL1
Atkinson, TM1
Halabi, S4
Bennett, AV1
Rogak, L1
Sit, L1
Li, Y1
Kaplan, E1
Basch, E1
Sauer, H2
Stanelle, R1
Hescheler, J2
Wartenberg, M2
Small, EJ7
Ratain, MJ6
Rosner, G1
Stadler, W2
Palchak, D2
Marshall, E1
Rago, R4
Hars, V1
Wilding, G7
Petrylak, D2
Vogelzang, NJ8
Autorino, R1
Di Lorenzo, G1
Damiano, R1
De Placido, S1
D'Armiento, M1
Xing, YF1
Lu, GC1
Xiao, YJ1
Zeng, FQ1
Zhang, QJ1
Feng, W1
Karrison, T1
Stadler, WM1
Garcia, J1
Cohn, H1
Kugler, J1
Troeger, T1
Giannone, L1
Arrieta, R1
Vokes, EE4
Cao, LY1
Huang, H1
Ni, JH1
Ahles, TA1
Herndon, JE1
Kornblith, AB1
Marshall, ME2
Holland, JC1
Wilson, S1
Greer, B1
Hooper, J1
Zijlstra, A1
Walker, B1
Quigley, J1
Hawthorne, S1
Zhao, L1
Wientjes, MG5
Au, JL5
Bhandari, MS1
Petrylak, DP4
Hussain, M2
DeAntoni, E1
Crawford, ED2
Tatoud, R1
Desgrandchamps, F1
DeGeorges, A1
Thomas, F1
Peehl, DM2
Leung, GK1
Wong, ST2
Kantoff, PW2
Kelly, WK4
Curley, T5
Leibretz, C1
Dnistrian, A2
Schwartz, M2
Scher, HI10
Tu, SM2
McConnell, K1
Marin, MC1
Campbell, ML1
Fernandez, A1
von Eschenbach, AC2
McDonnell, TJ1
Kehinde, EO1
Terry, TR1
Mistry, N1
Horsburgh, T1
Sandhu, DP1
Bell, PR1
Rosen, P1
Belldegrun, A2
Steineck, G1
Redman, BG1
Pienta, KJ4
Clark, JW1
Chabner, BA1
Eisenberger, MA12
Sinibaldi, VJ8
Reyno, LM8
Sridhara, R6
Jodrell, DI4
Zuhowski, EG4
Tkaczuk, KH3
Lowitt, MH2
Hemady, RK2
Jacobs, SC3
Egorin, MJ6
Kobayashi, K4
Janish, L1
Soliven, B2
Mazumdar, M1
Pfister, D1
Leibertz, C1
Cohen, L1
Vlamis, V1
Bitton, RJ2
Figg, WD13
Venzon, DJ1
Dalakas, MC1
Bowden, C1
Headlee, D5
Reed, E8
Myers, CE17
Cooper, MR10
Donat, SM1
Powell, CT1
Israeli, RS1
Fair, WR1
Heston, WD2
Mitchen, J2
Myers, C2
Trepel, J1
Sartor, O9
Cooper, M2
Ranson, M2
Toko, T1
Linehan, MW1
van Rijswijk, RE2
Cvitkovic, E1
Wagstaff, J2
Cheson, BD1
Phillips, PH1
Kaplan, RS1
Yoneda, T1
Williams, P1
Rhine, C1
Boyce, BF1
Dunstan, C1
Mundy, GR1
Pollak, M1
Katz, SK1
Medenica, MM1
Soltani, K1
Lopez Lopez, R1
Pinedo, HM2
Peters, GJ2
Lopez, R1
Smitskamp-Wilms, E1
Virizuela, JA1
van Ark-Otte, J1
Giaccone, G1
Kyprianou, N3
Qiao, L1
Pizzolo, JG1
Melamed, MR1
Okada, K2
Akino, H2
Suzuki, Y2
Miwa, Y2
Saikawa, S2
Fujita, T2
Aoki, Y1
Iwaoka, K1
Woll, PJ1
Margison, J1
Thomson, Y1
van der Water, L1
George, N1
Howell, A1
Stevens, JA1
August, EM1
Duncan, KL1
Malinowski, NM1
Cysyk, RL1
Thibault, A2
Humphrey, J1
Bergan, RC4
Myers, RB1
Parker, M1
Grizzle, WE1
Rago, RP2
Miles, JM1
Sufit, RL1
Spriggs, DR1
Wichterich, K1
Tebbe, B1
Handke, A1
Dieckmann, KP1
Gollnick, H1
Khleif, SN1
Rosell, D1
Robles, JE1
Aguera, L1
Abad, JI1
Rodríguez-Rubio, FI1
Zudaire, JJ1
Berian, JM2
Schulze, H2
Sommerfeld, HJ1
Novak, MJ1
Kanimoto, Y1
Rapoport, BL1
Falkson, G1
Raats, JI1
de Wet, M1
Lotz, BP1
Potgieter, HC1
Yamazaki, H1
Dilworth, A1
Sinha, BK2
Sklar, GN1
Eddy, HA1
Ewing, MW3
Liu, SC1
Gnarra, JR1
Walther, MM4
Meyers, CE1
Linehan, WM6
Samid, D1
Shack, S1
Tisdale, JF1
McCall, NA1
Alkins, BR1
Horne, MK1
Saffrin, R1
Chou, P1
Ray, V1
Shaw, M1
Rubenstein, M1
Guinan, P1
Rosen, PJ1
Mendoza, EF1
Landaw, EM1
Mondino, B1
Graves, MC1
McBride, JH1
Turcillo, P1
deKernion, J1
Dawson, NA7
Headlee, DJ2
Steinberg, SM5
Sausville, EA2
Nelson, WG1
Thalmann, GN1
Sikes, RA1
Chang, SM1
Johnston, DA1
Chung, LW1
Panvichian, R1
Mahler, C2
Verhelst, J1
Denis, L1
Lush, RM1
Tompkins, AC1
Weiss, RE1
Janisch, L2
Chatterjee, D1
Wyche, JH1
Pantazis, P1
Bowden, CJ1
Weinberger, MS1
Dhand, UK1
Arora, R1
Martin, B1
Petersen, MV1
Chaudhry, V1
Sheikh, K1
Griffin, JW1
Cornblath, DR1
Siu, LL1
Moore, MJ2
Konety, BR1
Getzenberg, RH1
Senderowicz, AM1
Tompkins, A2
Weinberger, B1
Abi-Rashid, B1
Palayoor, ST1
Bump, EA1
Teicher, BA1
Coleman, CN1
Smith, A1
Harbour, D1
Liebmann, J1
Miglietta, L1
Canobbio, L1
Granetto, C1
Vannozzi, MO1
Esposito, M1
Boccardo, F1
Bains, A1
Rhee, JG1
Walls, RG1
Waselenko, JK1
Kenner, JR1
Sperling, LC1
Waselenko, J1
Dawson, N3
Sau, P1
Moul, JW1
Brawley, OW1
Bergan, R1
Senderowicz, A1
Sutherland, M1
Patronas, N1
Sausville, E1
Gill, JS2
Windebank, AJ2
Pagliaro, LC1
Banks, ME1
Amato, RJ1
Millikan, RE1
Bugazia, NA1
Madden, T1
Newman, RA1
Logothetis, CJ2
Kobayashi, T1
Koshida, K1
Endo, Y1
Imao, T1
Uchibayashi, T1
Sasaki, T1
Namiki, M1
Nishimaki, T1
Furudate, S1
Günther, J1
Stein, CA1
Khan, TM1
Khaled, Z1
Tonkinson, JL1
Gan, Y2
Lu, J1
Church, D1
Zhang, Y2
Lara, PN1
Meyers, FJ2
Garcia-Schürmann, JM1
Haupt, G1
Pastor, J1
Allolio, B1
Senge, T1
Kim, J1
Smith, DC1
Falcone, A1
Antonuzzo, A1
Danesi, R3
Allegrini, G1
Monica, L1
Pfanner, E1
Masi, G1
Ricci, S1
Del Tacca, M1
Conte, P1
Arah, IN1
Dixon, SC1
Horti, J1
Beedassy, A1
Cardi, G1
Fisher, EI1
O'Connor, J1
Wood, DP1
Meyer, M3
Natale, RB2
Lenehan, PF2
Chen, L3
Slichenmyer, WJ2
Eisenberger, M2
Slusher, BS1
Tiffany, CW1
Merion, A1
Lapidus, RG1
Jackson, PF1
Song, S3
Roth, BJ1
Rehak, NN1
Venzon, D1
Heidenreich, A1
von Knobloch, R1
Hofmann, R1
McMillan, A1
Bok, RA1
Fei, DT1
Rodriquez, CR1
Hayes, DF2
Kantoff, P1
Shuman, MA1
Jeong, E1
Bolinger, B1
Lenehan, P1
Slichenmyer, W1
Farmer, DA1
Vogelzang, NA1
Walsh, C1
Knox, JJ1
Yang, F1
Russell, JW1
Sorenson, EJ1
Schultz, DA1
Calvo, E1
Cortés, J1
Rodríguez, J1
Sureda, M1
Beltrán, C1
Rebollo, J1
Martínez-Monge, R1
de Irala, J1
Brugarolas, A1
Heicappell, R1
Li, H1
Fang, W1
He, C1
You, J1
Heng, W1
Zheng, J1
Wu, B1
Kaur, M1
Dahut, W1
Harland, SJ2
McLellan, CA1
Borner, MM1
Yeh, S2
Tong, W2
O'Moore, PV1
Larson, S1
Iversen, JM2
O'Dell, M1
Larson, SM1
Stein, C1
LaRocca, R1
Weiss, G1
Choyke, P1
Steinberg, S1
Uhrich, MM1
Li, Z1
Geller, NL1
Brazy, PC1
O'Donnell, BP1
Weiss, RB1
James, WD1
Daugherty, RL1
Cockett, AT1
Schoen, SR1
Sluss, PM1
Duchesne, GM1
Coffey, DS2
Stamey, TA1
Kriegmair, M1
Schmeller, NT1
Forrest, A1
Fontana, JA1
Cheng, AL1
Oberley, T1
La Rocca, RV2
Jamis-Dow, CA1
Liu, S1
Anglard, P1
Trahan, E1
Brandsteterová, E1
Chovancová, V1
Koza, I1
Mardiak, J1
Hal'ko, J1
Knabbe, C1
Kellner, U1
Schmahl, M1
Voigt, KD1
Isaacs, WB2
Vindivich, D1
LaRocca, RV1
Uhrich, M1
Kim, JH1
Sherwood, ER1
Sutkowski, DM1
Lee, C1
Kozlowski, JM1
Van Oosterom, AT1
De Smedt, EA1
Denis, LJ1
de Bruijn, EA1
Berns, EM1
Schuurmans, AL1
Bolt, J1
Lamb, DJ1
Foekens, JA1
Mulder, E1
Morton, RA1
Isaacs, JT1
Fruehauf, JP1
Corliss, J1

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A PHASE III STUDY OF THREE DIFFERENT DOSES OF SURAMIN (NSC #34936) ADMINISTERED WITH A FIXED DOSING SCHEDULE IN PATIENTS WITH ADVANCED PROSTATE CANCER[NCT00002723]Phase 3390 participants (Actual)Interventional1996-01-31Completed
Phase II Trial of Phenylbutyrate Given as a Continuous Infusion in Pediatric Patients With Progressive or Recurrent CNS Malignancy[NCT00006450]Phase 2120 participants Interventional2000-11-30Completed
Phase I and Pharmacokinetic Trial of Phenylbutyrate Given as a Continuous Infusion in Pediatric Patients With Refractory Malignancy[NCT00001565]Phase 135 participants Interventional1996-12-31Completed
A Phase II Study of AZD2171 in Metastatic Androgen Independent Prostate Cancer[NCT00436956]Phase 259 participants (Actual)Interventional2006-10-16Completed
A Phase II Study of Oral Calcitriol in Combination With Ketoconazole in Castration Resistant Prostate Cancer, Progressing Despite Primary ADT and Abiraterone[NCT03261336]Phase 21 participants (Actual)Interventional2017-01-06Terminated (stopped due to can not meet enrollment)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Median Overall Survival

Time from treatment start date until date of death or date last known alive. (NCT00436956)
Timeframe: 44 months

InterventionMonths (Median)
20 mg AZD2171 Daily11.7
20 mg AZD2171 + 10mg Prednisone Daily9.9

Median Progression Free Survival (PFS)

Time interval from start of treatment to documented evidence of disease progression. (NCT00436956)
Timeframe: up to 14.9 months based on a Kaplan-Meier analysis.

InterventionMonths (Median)
20 mg AZD2171 Daily3.6
20 mg AZD2171 + 10mg Prednisone Daily3.7

Number of Participants With Adverse Events

Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module. (NCT00436956)
Timeframe: Date treatment consent signed to date off study, approximately 61.5 months

InterventionParticipants (Count of Participants)
All Participants- AZD2171 & Prednisone59

Percent Probability of Participants With 6-month Progression-free Survival (PFS)

PFS is the proportion of subjects who progress or die by 6 months after the start of the combined therapy. PFS is determined by prostatic specific antigen (PSA) consensus criteria and the Response Evaluation Criteria in Solid Tumors (RECIST). PSA consensus criteria is defined as PSA decline of >/= 50% or PSA progression. RECIST is defined as the following: Complete response (CR) is disappearance of all target lesions; partial response (PR) is at least a 30% decline in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD; and stable disease is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease ((PD) at least a 20% increase in the sum of the LD of target lesions, or the appearance of one or more lesions), taking as reference the smallest sum LD since the treatment started. Data is estimated and the probability of PFS as a function of time was determined using the Kaplan-Meier method. (NCT00436956)
Timeframe: 6 months

Interventionpercent probability (Number)
All Participants - AZD2171 & Prednisone43.9

Number of Grade 2 Toxicities

Here is the number of Grade 2 (moderate) toxicities. (NCT00436956)
Timeframe: 61.5 months

,
Interventiontoxicities (Number)
HypertensionFatigueAnorexiaWeight lossHypothyroidismDehydrationProlonged QTcNauseaDiarrheaHypoalbuminemiaProteinuriaElevated alkaline phosphataseAspartate transaminaseVomitingHyperbilirubinemiaMuscle weakness
20 mg AZD2171 + 10mg Prednisone Daily8464622303323211
20 mg AZD2171 Daily17151211788785543442

Number of Grade 3 Toxicities

Here is the number of Grade 3 (severe) toxicities. (NCT00436956)
Timeframe: 61.5 months

,
Interventiontoxicities (Number)
HypertensionFatigueAnorexiaWeight lossHypothyroidismDehydrationProlonged QTcNauseaDiarrheaHypoalbuminemiaProteinuriaElevated alkaline phosphataseAspartate transaminaseVomitingHyperbilirubinemiaMuscle weakness
20 mg AZD2171 + 10mg Prednisone Daily0210031000000001
20 mg AZD2171 Daily0412031100052113

Response Per the Response Evaluation Criteria in Solid Tumors (RECIST)

Response was evaluated by the RECIST. Complete response (CR) is disappearance of all target lesions. Partial response (PR) is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. Progressive disease (PD)is at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. Stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. (NCT00436956)
Timeframe: Every 2 cycles (approximately 56 days)

InterventionParticipants (Count of Participants)
Complete ResponseConfirmed Partial ResponseUnconfirmed Partial ResponseNot Evaluable
All Participants - AZD2171 & Prednisone0611

Toxicity and Tolerability of Experimental Arm

Descriptive analysis of observed toxicity and patient reports of tolerating experimental treatment (NCT03261336)
Timeframe: 2 years

InterventionParticipants (Count of Participants)
Calcitriol, Ketoconazole, Hydrocortisone1

Reviews

33 reviews available for suramin and Prostatic Neoplasms

ArticleYear
Role of chemotherapy in hormone-refractory prostate cancer. Old issues, recent advances and new perspectives.
    Urologia internationalis, 2003, Volume: 70, Issue:1

    Topics: Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Biopsy, Needle; Bridge

2003
[Progress in researches on drugs for prostate cancer].
    Zhonghua nan ke xue = National journal of andrology, 2003, Volume: 9, Issue:9

    Topics: Androgen Antagonists; Antineoplastic Agents; Goserelin; Humans; Male; Prostatic Neoplasms; Sulfonami

2003
Clinical trials in metastatic prostate cancer--has there been real progress in the past decade?
    European journal of cancer (Oxford, England : 1990), 2005, Volume: 41, Issue:6

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Clinical Trials a

2005
[Recent multicenter study protocols in the USA for patients with metastatic prostatic carcinoma].
    Der Urologe. Ausg. A, 1995, Volume: 34, Issue:5

    Topics: Antineoplastic Agents, Hormonal; Combined Modality Therapy; Flutamide; Humans; Leuprolide; Male; Mul

1995
[Peptide growth factors in the prostate].
    Pathologie-biologie, 1993, Volume: 41, Issue:8

    Topics: Adenocarcinoma; Epidermal Growth Factor; Fibroblast Growth Factors; Humans; Interleukin-6; Male; Ner

1993
New agents in the therapy of hormone-refractory patients with prostate cancer.
    Seminars in oncology, 1995, Volume: 22, Issue:1 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Humans; Male; Mitoxantrone; Prostate

1995
Hormone-refractory (D3) prostate cancer: refining the concept.
    Urology, 1995, Volume: 46, Issue:2

    Topics: Aminoglutethimide; Clinical Trials as Topic; Cortisone; Dexamethasone; Drug Therapy, Combination; Hu

1995
New treatment strategies for hormone refractory prostate cancer.
    Seminars in urology, 1995, Volume: 13, Issue:2

    Topics: Estramustine; Etoposide; Humans; Male; Prostatic Neoplasms; Suramin; Vinblastine

1995
Apoptosis: therapeutic significance in the treatment of androgen-dependent and androgen-independent prostate cancer.
    World journal of urology, 1994, Volume: 12, Issue:6

    Topics: Androgens; Animals; Antineoplastic Agents; Apoptosis; Combined Modality Therapy; Humans; Male; Prost

1994
[Treatment of advanced prostate cancer].
    Hinyokika kiyo. Acta urologica Japonica, 1994, Volume: 40, Issue:10

    Topics: Animals; Antineoplastic Agents; Combined Modality Therapy; Diphosphonates; Humans; Male; Mice; Mice,

1994
Suramin.
    Cancer treatment reviews, 1994, Volume: 20, Issue:3

    Topics: Drug Administration Schedule; Drug Monitoring; Humans; Male; Neoplasms; Prostatic Neoplasms; Suramin

1994
Prostate cancer: how can a common disease be so controversial?
    Current opinion in oncology, 1994, Volume: 6, Issue:3

    Topics: Cell Differentiation; Humans; Male; Neoplasm Staging; Oncogenes; Prostatectomy; Prostatic Neoplasms;

1994
[Immunotherapy of prostate cancer].
    Der Urologe. Ausg. A, 1993, Volume: 32, Issue:5

    Topics: Antibodies, Monoclonal; Coumarins; Humans; Immunotherapy; Immunotherapy, Active; Immunotherapy, Adop

1993
The treatment of hormone refractory prostate cancer.
    Comprehensive therapy, 1996, Volume: 22, Issue:2

    Topics: Androgen Antagonists; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Estramu

1996
Other chemotherapy regimens including mitoxantrone and suramin.
    Seminars in urologic oncology, 1997, Volume: 15, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyc

1997
Novel therapies for advanced prostate cancer.
    Seminars in urologic oncology, 1997, Volume: 15, Issue:1

    Topics: Animals; Antineoplastic Agents; Bombesin; Diet; Enzyme Inhibitors; Epoprostenol; Genetic Therapy; Hu

1997
Therapy for hormone-resistant prostate cancer: no longer a myth.
    Cancer treatment and research, 1996, Volume: 88

    Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Ne

1996
Treatment options in androgen-independent prostate cancer.
    Cancer investigation, 1999, Volume: 17, Issue:2

    Topics: Adenocarcinoma; Androgen Antagonists; Androgens; Antibodies, Monoclonal; Antineoplastic Agents; Anti

1999
Serologic tumor markers, clinical biology, and therapy of prostatic carcinoma.
    The Urologic clinics of North America, 1999, Volume: 26, Issue:2

    Topics: Androgen Antagonists; Antineoplastic Agents; Cyclohexanes; Humans; Male; O-(Chloroacetylcarbamoyl)fu

1999
Chemotherapy for hormone refractory prostate cancer.
    The Urologic clinics of North America, 1999, Volume: 26, Issue:2

    Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cyclophosphamide; Estr

1999
Differentiating agents and nontoxic therapies.
    The Urologic clinics of North America, 1999, Volume: 26, Issue:2

    Topics: Antineoplastic Agents; Cell Transformation, Neoplastic; Fatty Acids; Humans; Male; Phenylacetates; P

1999
Chemotherapy in advanced prostate cancer.
    Seminars in oncology, 1999, Volume: 26, Issue:4

    Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Clinical

1999
Androgen-independent prostate cancer: not so chemorefractory after all.
    Seminars in oncology, 1999, Volume: 26, Issue:6 Suppl 18

    Topics: Antineoplastic Combined Chemotherapy Protocols; Estramustine; Humans; Male; Mitoxantrone; Prostatic

1999
Current status of cytotoxic chemotherapy in hormone refractory prostate cancer.
    European urology, 2001, Volume: 39, Issue:2

    Topics: Anthracyclines; Antineoplastic Agents; Estramustine; Humans; Male; Prognosis; Prostatic Neoplasms; R

2001
Treatment of hormone refractory prostate cancer.
    Seminars in urologic oncology, 2001, Volume: 19, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Est

2001
Controversies in chemotherapy of prostate cancer.
    Frontiers of radiation therapy and oncology, 2002, Volume: 36

    Topics: Adenocarcinoma; Adrenal Cortex Hormones; Androgen Antagonists; Antigens, Neoplasm; Antineoplastic Ag

2002
Suramin's development: what did we learn?
    Investigational new drugs, 2002, Volume: 20, Issue:2

    Topics: Antineoplastic Agents; Clinical Trials as Topic; Half-Life; Humans; Male; Metabolic Clearance Rate;

2002
Hormone refractory prostatic cancer: the role of radiolabelled diphosphonates and growth factor inhibitors.
    Advances in experimental medicine and biology, 1992, Volume: 324

    Topics: Animals; Bone Neoplasms; Dogs; Drug Screening Assays, Antitumor; Etidronic Acid; Growth Substances;

1992
Suramin as an archetypical compound in the development of growth factor antagonists for inhibition of genitourinary tumors.
    Cancer treatment and research, 1992, Volume: 59

    Topics: Growth Inhibitors; Humans; Male; Prostatic Neoplasms; Suramin; Tumor Cells, Cultured; Urogenital Neo

1992
Therapeutic alternatives for hormone-refractory prostatic cancer.
    Seminars in urology, 1992, Volume: 10, Issue:1

    Topics: Antigens, Neoplasm; Biomarkers, Tumor; Bone Neoplasms; Combined Modality Therapy; Humans; Immunother

1992
Cell motility as a chemotherapeutic target.
    Cancer surveys, 1991, Volume: 11

    Topics: Animals; Antibodies; Antineoplastic Agents, Phytogenic; Cell Division; Cell Movement; Cytoskeleton;

1991
[New substances in therapy of advanced prostate cancer].
    Fortschritte der Medizin, 1991, Sep-30, Volume: 109, Issue:28

    Topics: Androgen Antagonists; Humans; Imidazoles; Immunologic Factors; Male; Neoplasm Staging; Palliative Ca

1991
Use of suramin in treatment of prostatic carcinoma refractory to conventional hormonal manipulation.
    The Urologic clinics of North America, 1991, Volume: 18, Issue:1

    Topics: Adrenal Cortex; Animals; Enzymes; Growth Substances; Humans; Male; Prostatic Neoplasms; Suramin; Tum

1991

Trials

39 trials available for suramin and Prostatic Neoplasms

ArticleYear
Measurement of affective and activity pain interference using the Brief Pain Inventory (BPI): Cancer and Leukemia Group B 70903.
    Pain medicine (Malden, Mass.), 2012, Volume: 13, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Factor Analysis, Statistical;

2012
Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Aug-15, Volume: 20, Issue:16

    Topics: Aged; Antineoplastic Agents; Disease-Free Survival; Dose-Response Relationship, Drug; Humans; Male;

2002
A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma.
    Cancer, 2004, Jan-01, Volume: 100, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Carcinoma; D

2004
Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480.
    Cancer, 2004, Nov-15, Volume: 101, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormon

2004
Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:9

    Topics: Aged; Drug Administration Schedule; Drug Therapy, Combination; Humans; Hydrocortisone; Infusions, In

1995
UK studies on suramin therapy in hormone resistant prostate cancer.
    Cancer surveys, 1995, Volume: 23

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance; Flutamide; Humans; Male; Midd

1995
Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:9

    Topics: Adaptation, Physiological; Aged; Anorexia; Bayes Theorem; Cohort Studies; Drug Monitoring; Drug Resi

1995
Development and validation of a pharmacokinetically based fixed dosing scheme for suramin.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Disease-Free Survival; Drug Administration Schedule; Drug Monitoring

1995
Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:9

    Topics: Adaptation, Physiological; Adult; Aged; Cohort Studies; Drug Administration Schedule; Drug Monitorin

1995
Suramin and hydrocortisone: determining drug efficacy in androgen-independent prostate cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:9

    Topics: Adaptation, Physiological; Aged; Aged, 80 and over; Anemia; Cohort Studies; Drug Administration Sche

1995
Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Humans; Logistic Models; Male; Melanoma; Middle Aged; Motor Neuron D

1995
Antigrowth factor strategies.
    Cancer, 1993, Feb-01, Volume: 71, Issue:3 Suppl

    Topics: Apoptosis; Cell Division; Extracellular Matrix; Growth Inhibitors; Growth Substances; Humans; Male;

1993
Suramin for breast and prostate cancer: a pilot study of intermittent short infusions without adaptive control.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1994, Volume: 5, Issue:7

    Topics: Adult; Aged; Ambulatory Care; Breast Neoplasms; Drug Administration Schedule; Feasibility Studies; F

1994
Suramin-induced weakness from hypophosphatemia and mitochondrial myopathy. Association of suramin with mitochondrial toxicity in humans.
    Cancer, 1994, Apr-01, Volume: 73, Issue:7

    Topics: Electron Transport Complex IV; Fanconi Syndrome; Humans; Hypophosphatemia; Male; Mitochondria, Muscl

1994
Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Bayes Theorem; Drug Administration Schedule; Feasibility Studies

1994
Suramin in combination with mitomycin C in hormone-resistant prostate cancer. A phase II clinical study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1993, Volume: 4, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Resistance; Humans; Male; Mitomycin; Prostatic

1993
Suramin, an active drug for prostate cancer: interim observations in a phase I trial.
    Journal of the National Cancer Institute, 1993, Apr-21, Volume: 85, Issue:8

    Topics: Aged; Antineoplastic Agents; Drug Administration Schedule; Humans; Infusions, Intravenous; Male; Mid

1993
Severe thrombocytopenia in patients treated with suramin: evidence for an immune mechanism in one.
    American journal of hematology, 1996, Volume: 51, Issue:2

    Topics: Antineoplastic Agents; Humans; Immunoglobulin G; Male; Middle Aged; Neoplasm Metastasis; Platelet Ag

1996
Suramin as adjuvant therapy with radical prostatectomy.
    The Prostate, 1996, Volume: 28, Issue:5

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Cyclophos

1996
Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:5

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Ambulatory Care; Half-Life; Humans; Male; Middle Aged; Neop

1996
Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables.
    Cancer, 1995, Aug-01, Volume: 76, Issue:3

    Topics: Aged; Antineoplastic Agents; Flutamide; Humans; Hydrocortisone; Male; Middle Aged; Prospective Studi

1995
Mineralocorticoid insufficiency due to suramin therapy.
    Cancer, 1996, Dec-01, Volume: 78, Issue:11

    Topics: Addison Disease; Adrenal Cortex Diseases; Adrenocorticotropic Hormone; Aged; Aldosterone; Antineopla

1996
A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: toxicity and response.
    Cancer chemotherapy and pharmacology, 1996, Volume: 39, Issue:1-2

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Dose-Response Relat

1996
Evaluation of neuropathy in patients on suramin treatment.
    Muscle & nerve, 1997, Volume: 20, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Demyelinating Diseases; Female; Humans; Male; Middle Aged; Motor Neu

1997
A prospective study of suramin-induced peripheral neuropathy.
    Brain : a journal of neurology, 1996, Volume: 119 ( Pt 6)

    Topics: Aged; Antineoplastic Agents; Axons; Clinical Trials as Topic; Humans; Male; Middle Aged; Neural Cond

1996
Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Diseas

1997
Suramin/epidoxorubicin association in hormone-refractory prostate cancer: preliminary results of a pilot phase II study.
    Journal of cancer research and clinical oncology, 1997, Volume: 123, Issue:7

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Humans; Male; Pilot Proj

1997
Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1998, Volume: 4, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Aminoglutethimide; Androgen Antagonists; Antineoplastic Combined Che

1998
Phase I study of suramin combined with doxorubicin in the treatment of androgen-independent prostate cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1998, Volume: 4, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Digestive System; Do

1998
Suramin treatment in hormone- and chemotherapy-refractory prostate cancer.
    Urology, 1999, Volume: 53, Issue:3

    Topics: Aged; Analgesia; Antineoplastic Agents; Humans; Male; Middle Aged; Pain; Prostatic Neoplasms; Surami

1999
Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma.
    Cancer, 1999, Aug-01, Volume: 86, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bayes The

1999
Androgen deprivation and four courses of fixed-schedule suramin treatment in patients with newly diagnosed metastatic prostate cancer: A Southwest Oncology Group Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:5

    Topics: Adult; Aged; Androgens; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protoc

2000
Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Dise

2000
Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Mar-01, Volume: 19, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Biomarkers, Tumor; Dis

2001
Phase 1 drug interaction study of suramin and warfarin in patients with prostate cancer.
    American journal of clinical oncology, 2001, Volume: 24, Issue:2

    Topics: Anti-Inflammatory Agents; Anticoagulants; Antineoplastic Agents; Blood Coagulation; Drug Interaction

2001
Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Jun-15, Volume: 19, Issue:12

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Biomarkers, Tumor; Drug Resistance, Neoplasm; Humans; M

2001
Fixed higher dose schedule of suramin plus hydrocortisone in patients with hormone refractory prostate carcinoma a multicenter Phase II study.
    Cancer, 2001, Nov-01, Volume: 92, Issue:9

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease Progress

2001
Hormone refractory prostatic cancer: the role of radiolabelled diphosphonates and growth factor inhibitors.
    Advances in experimental medicine and biology, 1992, Volume: 324

    Topics: Animals; Bone Neoplasms; Dogs; Drug Screening Assays, Antitumor; Etidronic Acid; Growth Substances;

1992
Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992, Volume: 10, Issue:6

    Topics: Aged; Aged, 80 and over; Antigens, Neoplasm; Biomarkers, Tumor; Bone Neoplasms; Growth Inhibitors; H

1992

Other Studies

84 other studies available for suramin and Prostatic Neoplasms

ArticleYear
Spatial modeling of prostate cancer metabolic gene expression reveals extensive heterogeneity and selective vulnerabilities.
    Scientific reports, 2020, 02-26, Volume: 10, Issue:1

    Topics: Arachidonic Acid; Cysteine; Databases, Factual; Humans; Male; Metabolic Networks and Pathways; Organ

2020
The DC electrical-field-induced Ca(2+) response and growth stimulation of multicellular tumor spheroids are mediated by ATP release and purinergic receptor stimulation.
    Journal of cell science, 2002, Aug-15, Volume: 115, Issue:Pt 16

    Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Apyrase; Calcium; Calcium Signaling; Cell Di

2002
[Influence of suramin on the proliferation of prostatic carcinoma cells PC-3M].
    Zhonghua nan ke xue = National journal of andrology, 2003, Volume: 9, Issue:5

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cattle; Cell Cycle; Cell Line, Tumor; Cell Proliferation;

2003
The membrane-anchored serine protease, TMPRSS2, activates PAR-2 in prostate cancer cells.
    The Biochemical journal, 2005, Jun-15, Volume: 388, Issue:Pt 3

    Topics: Boron Compounds; Calcium; Catalysis; Cell Line, Tumor; Humans; Male; Prostatic Neoplasms; Receptor,

2005
Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Dec-01, Volume: 10, Issue:23

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Interactions; Inhibitory

2004
Keratin expression: a measure of phenotypic modulation of human prostatic epithelial cells by growth inhibitory factors.
    Cell and tissue research, 1994, Volume: 277, Issue:1

    Topics: Cell Division; Cells, Cultured; Epithelial Cells; Epithelium; Glucose; Growth Substances; Humans; In

1994
Combination adriamycin and suramin induces apoptosis in bcl-2 expressing prostate carcinoma cells.
    Cancer letters, 1995, Jul-13, Volume: 93, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Doxorubicin; Drug Resistance; Dr

1995
American studies on suramin therapy in hormone resistant prostate cancer.
    Cancer surveys, 1995, Volume: 23

    Topics: Drug Resistance; Flutamide; Humans; Male; Prostatic Neoplasms; Suramin

1995
Suramin and prostate cancer: where do we go from here?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:9

    Topics: Drug Monitoring; Humans; Male; Prostatic Neoplasms; Suramin; Survival Rate

1995
Reversal by transferrin of growth-inhibitory effect of suramin on hormone-refractory human prostate cancer cells.
    Journal of the National Cancer Institute, 1995, Jan-04, Volume: 87, Issue:1

    Topics: Androgens; Apoproteins; Humans; Male; Prostatic Neoplasms; Receptors, Transferrin; RNA, Messenger; S

1995
Effects of suramin on the proliferation of primary epithelial cell cultures derived from normal, benign hyperplastic and cancerous human prostates.
    The Prostate, 1993, Volume: 22, Issue:1

    Topics: Cell Adhesion; Cell Division; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Epit

1993
Workshop on suramin with emphasis on prostate cancer: re-evaluation of response criteria.
    European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A, Issue:3

    Topics: Bone Neoplasms; Humans; Male; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Suramin

1993
Clinical trials referral resource. Prostate cancer II.
    Oncology (Williston Park, N.Y.), 1995, Volume: 9, Issue:1

    Topics: Clinical Trials, Phase III as Topic; Drug Administration Schedule; Humans; Male; Prostatic Neoplasms

1995
Suramin suppresses hypercalcemia and osteoclastic bone resorption in nude mice bearing a human squamous cancer.
    Cancer research, 1995, May-01, Volume: 55, Issue:9

    Topics: Adenocarcinoma; Animals; Bone and Bones; Bone Resorption; Calcium; Carcinoma, Squamous Cell; Cell Di

1995
Re: Reversal by transferrin of growth-inhibitory effect of suramin on hormone-refractory human prostate cancer cells.
    Journal of the National Cancer Institute, 1995, Apr-19, Volume: 87, Issue:8

    Topics: Cell Division; Humans; In Vitro Techniques; Male; Prostatic Neoplasms; Suramin; Transferrin; Tumor C

1995
Erythema multiforme induced by suramin.
    Journal of the American Academy of Dermatology, 1995, Volume: 32, Issue:2 Pt 1

    Topics: Aged; Drug Eruptions; Erythema Multiforme; Humans; Injections, Intravenous; Male; Prostatic Neoplasm

1995
The synergistic and antagonistic effects of cytotoxic and biological agents on the in vitro antitumour effects of suramin.
    European journal of cancer (Oxford, England : 1990), 1994, Volume: 30A, Issue:10

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Divisi

1994
In vitro sequence-dependent synergistic effect of suramin and camptothecin.
    European journal of cancer (Oxford, England : 1990), 1994, Volume: 30A, Issue:11

    Topics: Camptothecin; Cell Cycle; Cell Division; DNA Topoisomerases, Type I; Dose-Response Relationship, Dru

1994
Effects of suramin on expression of proliferation associated nuclear antigens in DU-145 prostate carcinoma cells.
    Biochemical and biophysical research communications, 1994, Jun-15, Volume: 201, Issue:2

    Topics: Antigens, Neoplasm; Cell Cycle; Cell Division; Cell Line; Cyclins; DNA, Neoplasm; Dose-Response Rela

1994
Adaptive control with feedback of suramin using intermittent infusions.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:7

    Topics: Drug Administration Schedule; Humans; Infusions, Intravenous; Male; Prostatic Neoplasms; Suramin

1994
Inhibition of fibroblast hyaluronic acid production by suramin.
    Oncology research, 1993, Volume: 5, Issue:10-11

    Topics: 3T3 Cells; Animals; Cell Division; Culture Media; DNA; Dose-Response Relationship, Drug; Fibroblasts

1993
Acute renal toxicity associated with suramin in the treatment of prostate cancer.
    Cancer, 1994, Sep-01, Volume: 74, Issue:5

    Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined Modality Th

1994
The effects of coumarin and suramin on the growth of malignant renal and prostatic cell lines.
    Journal of cancer research and clinical oncology, 1994, Volume: 120 Suppl

    Topics: Carcinoma, Renal Cell; Cell Division; Coumarins; Humans; Kidney Neoplasms; Male; Prostatic Neoplasms

1994
[Cutaneous drug reaction caused by suramin in 4 patients with metastatic prostate cancer].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 1994, Volume: 45, Issue:2

    Topics: Aged; Biopsy; Drug Eruptions; Drug Therapy, Combination; Humans; Infusions, Intravenous; Male; Middl

1994
Suramin decreases circulating levels of insulin-like growth factor-I.
    The American journal of medicine, 1994, Volume: 96, Issue:4

    Topics: Analysis of Variance; Humans; Insulin-Like Growth Factor I; Male; Prospective Studies; Prostatic Neo

1994
[Potentiation of cytotoxicity of electromagnetic shock waves by suramin, "in vitro" study].
    Actas urologicas espanolas, 1994, Volume: 18, Issue:1

    Topics: Adenocarcinoma; Cell Division; Combined Modality Therapy; Dose-Response Relationship, Radiation; Hum

1994
[The enhancement of the chemotherapeutic effects on human prostate cancer cell--the combination with the growth factor interaction inhibitor (suramin)].
    Hinyokika kiyo. Acta urologica Japonica, 1993, Volume: 39, Issue:12

    Topics: Animals; Antineoplastic Agents; Cell Division; Cisplatin; Drug Interactions; Drug Synergism; Humans;

1993
Suramin inhibits DNA damage in human prostate cancer cells treated with topoisomerase inhibitors in vitro.
    The Prostate, 1993, Volume: 23, Issue:1

    Topics: Amsacrine; Camptothecin; Cell Survival; Chemical Precipitation; DNA Damage; Dose-Response Relationsh

1993
Combined antitumor effect of suramin plus irradiation in human prostate cancer cells: the role of apoptosis.
    The Journal of urology, 1993, Volume: 150, Issue:5 Pt 1

    Topics: Apoptosis; Clusterin; Combined Modality Therapy; DNA, Neoplasm; Dose-Response Relationship, Drug; Do

1993
Effect of suramin on the mitogenic response of the human prostate carcinoma cell line PC-3.
    Cancer, 1993, Feb-01, Volume: 71, Issue:3 Suppl

    Topics: Blotting, Northern; Cell Cycle; Cell Division; Culture Media, Serum-Free; Dose-Response Relationship

1993
Suramin: here to stay!?
    Journal of the National Cancer Institute, 1993, Apr-21, Volume: 85, Issue:8

    Topics: Antineoplastic Agents; Drug Administration Schedule; Humans; Male; Prostatic Neoplasms; Suramin

1993
Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate.
    The Journal of clinical investigation, 1993, Volume: 91, Issue:5

    Topics: Animals; Cell Division; Cell Survival; DNA Replication; Female; Glutamine; HLA-A3 Antigen; Humans; M

1993
Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate.
    The Journal of clinical investigation, 1993, Volume: 91, Issue:5

    Topics: Animals; Cell Division; Cell Survival; DNA Replication; Female; Glutamine; HLA-A3 Antigen; Humans; M

1993
Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate.
    The Journal of clinical investigation, 1993, Volume: 91, Issue:5

    Topics: Animals; Cell Division; Cell Survival; DNA Replication; Female; Glutamine; HLA-A3 Antigen; Humans; M

1993
Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate.
    The Journal of clinical investigation, 1993, Volume: 91, Issue:5

    Topics: Animals; Cell Division; Cell Survival; DNA Replication; Female; Glutamine; HLA-A3 Antigen; Humans; M

1993
Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:12

    Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Biomarker

1995
Ocular symptoms and signs associated with suramin sodium treatment for metastatic cancer of the prostate.
    American journal of ophthalmology, 1996, Volume: 121, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Corneal Diseases; Eye Diseases; Humans; Infus

1996
How much can we rely on the level of prostate-specific antigen as an end point for evaluation of clinical trials? A word of caution!
    Journal of the National Cancer Institute, 1996, Jun-19, Volume: 88, Issue:12

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Clinical Trials as Topic; Humans; Male; Predictive Value o

1996
Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer.
    Journal of the National Cancer Institute, 1996, Jun-19, Volume: 88, Issue:12

    Topics: Analysis of Variance; Androgens; Animals; Antineoplastic Agents; Blotting, Northern; Castration; Gen

1996
New molecules and treatment modulation in advanced prostatic cancer.
    Acta urologica Belgica, 1996, Volume: 64, Issue:2

    Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Flutamide; H

1996
Suramin-induced neutropenia.
    European journal of cancer (Oxford, England : 1990), 1996, Volume: 32A, Issue:9

    Topics: Adult; Aged; Antineoplastic Agents; Bayes Theorem; Fibroblast Growth Factor 2; Granulocyte Colony-St

1996
Induction of apoptosis in malignant and camptothecin-resistant human cells.
    Annals of the New York Academy of Sciences, 1996, Dec-13, Volume: 803

    Topics: Androgens; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Camptothecin; Cell Cycle; C

1996
Apoptosis and clonogenic cell death in PC3 human prostate cancer cells after treatment with gamma radiation and suramin.
    Radiation research, 1997, Volume: 148, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Survival; Combined Modality Therapy; DNA Fragment

1997
Acute renal failure in a patient receiving treatment with suramin.
    American journal of clinical oncology, 1997, Volume: 20, Issue:4

    Topics: Acute Kidney Injury; Adenocarcinoma; Androgen Antagonists; Anti-Inflammatory Agents; Antineoplastic

1997
Transient tyrosine phosphorylation of p34cdc2 is an early event in radiation-induced apoptosis of prostate cancer cells.
    The Prostate, 1997, Sep-01, Volume: 32, Issue:4

    Topics: Apoptosis; CDC2 Protein Kinase; Cell Survival; DNA Fragmentation; DNA, Neoplasm; Dose-Response Relat

1997
Similar clinical outcomes in African-American and non-African-American males treated with suramin for metastatic prostate cancer.
    Journal of the National Medical Association, 1997, Volume: 89, Issue:9

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Black People; Disease Progression; Humans; Male; Mid

1997
Management of progressive metastatic prostate cancer.
    Oncology (Williston Park, N.Y.), 1997, Volume: 11, Issue:10

    Topics: Androgen Antagonists; Androgens; Diphosphonates; Disease Progression; Hormones; Humans; Male; Prosta

1997
Suramin keratosis: a unique skin eruption in a patient receiving suramin for metastatic prostate cancer.
    The Journal of urology, 1997, Volume: 158, Issue:6

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Drug Eruptions; Humans; Keratosis; Male; Prostatic Neop

1997
Role of ceramide in suramin-induced cancer cell death.
    Cancer letters, 1997, Nov-11, Volume: 119, Issue:2

    Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Survival; Ceramides; DNA Fragmenta

1997
Evaluation of biomarkers of survival response in hormone-refractory prostate cancer patients treated with suramin.
    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 1998, Volume: 7, Issue:7

    Topics: Acid Phosphatase; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Bioma

1998
A chick embryo model for metastatic human prostate cancer.
    European urology, 1998, Volume: 34, Issue:2

    Topics: Animals; Antineoplastic Agents; Bone and Bones; Cell Division; Cell Transplantation; Chick Embryo; C

1998
The role of a new liquid-solid scintillator, a mixture of DPO, POPOP and Epon 812, for enhancement of autoradiograms with tritium agents.
    The Journal of veterinary medical science, 1998, Volume: 60, Issue:7

    Topics: Animals; Antineoplastic Agents; Autoradiography; Epoxy Resins; Humans; Indicators and Reagents; Male

1998
The embryoid body as a novel in vitro assay system for antiangiogenic agents.
    Laboratory investigation; a journal of technical methods and pathology, 1998, Volume: 78, Issue:10

    Topics: Animals; Capillaries; Cell Culture Techniques; Cell Differentiation; Cells, Cultured; Doxorubicin; E

1998
Cell surface binding and cellular internalization properties of suramin, a novel antineoplastic agent.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1995, Volume: 1, Issue:5

    Topics: Antineoplastic Agents; Binding, Competitive; Cell Membrane; Exocytosis; HL-60 Cells; Humans; Kinetic

1995
Antiproliferative and cytotoxic effects of geldanamycin, cytochalasin E, suramin and thiacetazone in human prostate xenograft tumor histocultures.
    Pharmaceutical research, 1998, Volume: 15, Issue:11

    Topics: Animals; Antineoplastic Agents; Benzoquinones; Cell Division; Culture Techniques; Cytochalasins; Hum

1998
Efficacy of suramin against human prostate carcinoma DU145 xenografts in nude mice.
    Cancer chemotherapy and pharmacology, 1999, Volume: 43, Issue:3

    Topics: Animals; Antineoplastic Agents; Dose-Response Relationship, Drug; Humans; Male; Mice; Mice, Inbred B

1999
Enhanced activity of estramustine, vinblastine, etoposide, and suramin in prostate carcinoma.
    Neoplasma, 1999, Volume: 46, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Division; Dose-Response Relationship, Drug; Dru

1999
Suramin potently inhibits the enzymatic activity of PSM.
    The Prostate, 2000, Jun-15, Volume: 44, Issue:1

    Topics: Antigens, Surface; Antineoplastic Agents; Carboxypeptidases; Chromatography, Ion Exchange; Dipeptide

2000
Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs.
    Proceedings of the National Academy of Sciences of the United States of America, 2000, Jul-18, Volume: 97, Issue:15

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Division; Culture Media, Conditioned; Doxorubic

2000
Suramin administration is associated with a decrease in serum calcium levels.
    World journal of urology, 2000, Volume: 18, Issue:6

    Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Com

2000
Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study.
    Cancer research, 2001, Mar-15, Volume: 61, Issue:6

    Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Clinical Trials, Ph

2001
Nontoxic doses of suramin enhance activity of paclitaxel against lung metastases.
    Cancer research, 2001, Aug-15, Volume: 61, Issue:16

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Culture Media, Conditioned; Dose-Response R

2001
Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors.
    The Journal of pharmacology and experimental therapeutics, 2001, Volume: 299, Issue:2

    Topics: Algorithms; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Culture Media, Conditioned;

2001
Suramin-induced neuropathy in an animal model.
    Journal of the neurological sciences, 2001, Nov-15, Volume: 192, Issue:1-2

    Topics: Animals; Antineoplastic Agents; Axons; Cell Size; Disease Models, Animal; Dose-Response Relationship

2001
[Activation of p38 and c-Jun NH2-terminal kinase mitogen-activated protein kinases in human prostate carcinoma cell lines with different metastatic potentials].
    Zhonghua bing li xue za zhi = Chinese journal of pathology, 2001, Volume: 30, Issue:3

    Topics: Adenosine Triphosphate; Cell Line, Tumor; Humans; Imidazoles; JNK Mitogen-Activated Protein Kinases;

2001
Suramin for prostate carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992, Volume: 10, Issue:12

    Topics: Humans; Hydrocortisone; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Suramin

1992
Suramin rapidly alters cellular tyrosine phosphorylation in prostate cancer cell lines.
    The Journal of clinical investigation, 1992, Volume: 90, Issue:6

    Topics: 3T3 Cells; Animals; Dose-Response Relationship, Drug; Humans; Male; Mice; Molecular Weight; Neoplasm

1992
Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone-refractory prostatic cancer treated with single-agent chemotherapy.
    Cancer, 1992, Dec-15, Volume: 70, Issue:12

    Topics: Aged; Analysis of Variance; Antineoplastic Agents; Humans; Male; Middle Aged; Neoplasms, Hormone-Dep

1992
Disruption of mitochondrial function by suramin measured by rhodamine 123 retention and oxygen consumption in intact DU145 prostate carcinoma cells.
    Cancer research, 1992, Dec-15, Volume: 52, Issue:24

    Topics: Adenosine Triphosphate; Fluorescent Dyes; Humans; Male; Mitochondria; Oxygen Consumption; Prostatic

1992
Suramin-induced skin reactions.
    Archives of dermatology, 1992, Volume: 128, Issue:1

    Topics: Carcinoma; Drug Eruptions; Drug Evaluation; Humans; Infusions, Intravenous; Male; Prostatic Neoplasm

1992
Suramin inhibits gonadotropin action in rat testis: implications for treatment of advanced prostate cancer.
    The Journal of urology, 1992, Volume: 147, Issue:3

    Topics: Animals; Cells, Cultured; Dose-Response Relationship, Drug; Follicle Stimulating Hormone; Luteinizin

1992
Suramin and prostate cancer: the role of hydrocortisone.
    European journal of cancer (Oxford, England : 1990), 1992, Volume: 28A, Issue:6-7

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Humans; Hydrocortisone; Mal

1992
Cytostatic effects of suramin on prostate cancer cells cultured from primary tumors.
    The Journal of urology, 1991, Volume: 145, Issue:3

    Topics: Cell Division; Growth Substances; Humans; Immunoblotting; In Vitro Techniques; Male; Prostate; Prost

1991
Use of adaptive control with feedback to individualize suramin dosing.
    Cancer research, 1992, Jan-01, Volume: 52, Issue:1

    Topics: Adenocarcinoma; Aged; Algorithms; Humans; Male; Middle Aged; Prostatic Neoplasms; Suramin; Time Fact

1992
Suramin, an active nonhormonal cytotoxic drug for treatment of prostate cancer: compelling reasons for testing in patients with hormone-refractory breast cancer.
    Journal of the National Cancer Institute, 1992, Jan-01, Volume: 84, Issue:1

    Topics: Antineoplastic Agents; Breast Neoplasms; Cell Division; Clinical Trials as Topic; Female; Humans; Ma

1992
Disruption of cellular energy balance by suramin in intact human prostatic carcinoma cells, a likely antiproliferative mechanism.
    Cancer research, 1991, Dec-15, Volume: 51, Issue:24

    Topics: Biological Transport; Calcium; Carcinoma; Cell Division; Energy Metabolism; Epidermal Growth Factor;

1991
Effect of suramin on human prostate cancer cells in vitro.
    The Journal of urology, 1991, Volume: 145, Issue:2

    Topics: Adenocarcinoma; Androstenedione; Antineoplastic Agents; Cell Line; Dehydroepiandrosterone; Dehydroep

1991
The effect of suramin, tumor necrosis factor and interferon gamma on human prostate carcinoma.
    The Journal of urology, 1991, Volume: 145, Issue:2

    Topics: Antineoplastic Agents; Cell Line; Drug Screening Assays, Antitumor; Humans; In Vitro Techniques; Int

1991
Determination of suramin in clinical samples using HPLC.
    Neoplasma, 1991, Volume: 38, Issue:4

    Topics: Antineoplastic Agents; Chemical Precipitation; Chromatography, High Pressure Liquid; Humans; Male; P

1991
Growth factors in human prostate cancer cells: implications for an improved treatment of prostate cancer.
    The Journal of steroid biochemistry and molecular biology, 1991, Volume: 40, Issue:1-3

    Topics: Cell Division; Culture Media, Serum-Free; Dihydrotestosterone; Epidermal Growth Factor; ErbB Recepto

1991
The effects of basic fibroblast growth factor and suramin on cell motility and growth of rat prostate cancer cells.
    The Journal of urology, 1991, Volume: 145, Issue:1

    Topics: Animals; Cell Movement; Cell Survival; Dose-Response Relationship, Drug; Drug Interactions; Drug Scr

1991
Inhibition of prostatic tumor cell proliferation by suramin: alterations in TGF alpha-mediated autocrine growth regulation and cell cycle distribution.
    The Journal of urology, 1991, Volume: 146, Issue:1

    Topics: Antineoplastic Agents; Cell Cycle; Cell Division; Cell Line; Depression, Chemical; Dose-Response Rel

1991
Suramin for prostatic cancer: a phase I/II study in advanced extensively pretreated disease.
    European journal of cancer (Oxford, England : 1990), 1990, Volume: 26, Issue:4

    Topics: Drug Administration Schedule; Drug Evaluation; Humans; Infusions, Intravenous; Male; Prostatic Neopl

1990
Antiproliferative effects of suramin on androgen responsive tumour cells.
    European journal of cancer (Oxford, England : 1990), 1990, Volume: 26, Issue:4

    Topics: Androgen Antagonists; Animals; Cell Cycle; Cell Division; Cricetinae; Drug Screening Assays, Antitum

1990
Differential effects of growth factor antagonists on neoplastic and normal prostatic cells.
    The Prostate, 1990, Volume: 17, Issue:4

    Topics: Animals; Growth Inhibitors; Male; Neoplasm Transplantation; Prostate; Prostatic Neoplasms; Protamine

1990
Synergistic activity of suramin with tumor necrosis factor alpha and doxorubicin on human prostate cancer cell lines.
    Journal of the National Cancer Institute, 1990, Jul-18, Volume: 82, Issue:14

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Division; Dose-Response Relationship, Drug; Dox

1990
Heparin analogues: a new family of anticancer drugs.
    Journal of the National Cancer Institute, 1989, Sep-20, Volume: 81, Issue:18

    Topics: Antineoplastic Agents; Humans; Kidney Neoplasms; Male; Prostatic Neoplasms; Suramin

1989